Future therapeutics: drugs that stop free radicals at their source
Research at the Buck Institute yields molecules that prevent free radical production by cells
September 15, 2016/Novato, California: Go to any health food store and you’re likely to see shelves crowded with antioxidants that promise to quell damage from free radicals, which are implicated in a myriad of human diseases and in the aging process itself. The problem is that antioxidants have failed to show benefits in several clinical trials and there is even some evidence they could be counterproductive.
Buck professor Martin Brand, PhD thinks that the current approaches to free radicals may fail because they apply a “sledgehammer” to a complex metabolic process that provides essential energy to our cells. “Rather than a sledgehammer that seeks to decrease the effects of free radicals, we’ve developed a scalpel that allows us to stop them from being produced in the first place,” he said. The results of the research will be published online in Cell Metabolism.
Free radicals are produced in the mitochondria – the energy-converting organelles which are abundant in almost every type of human cell. Highly-reactive free radicals, which oxidize cell constituents (hence the use of antioxidants), are spun-off as a normal byproduct of cellular bioenergetics; it’s a process that appears to go up when cells are stressed, something Brand says can occur with aging and disease.
A chain of electron transporters within the mitochondria is involved in the production of both free radicals and the chemical energy essential for life. The challenge has been to stop the free radicals without shutting down the cell's ability to release energy. Brand and his colleagues at the Genomics Institute of the Novartis Research Foundation (GNF) did that by painstakingly screening 635,000 small molecules in GNF’s academic library to single out the few that blocked free radical production at a specific site thought to be a major source of free radicals in the electron transport chain.
In this latest research, they demonstrated the potency and specificity of the successful molecules and tested their effects in cell culture, isolated hearts, and live models of disease. Brand says the compounds dramatically protected against reperfusion injury in a mouse heart model of ischemia. “Most of the lasting damage from heart attacks comes when blood flow is restored to the heart muscle,” he said. “These compounds have great potential as therapeutic leads for drugs that could be given following a heart attack or after stents have been inserted to open blocked coronary blood vessels.”
In addition, the molecules diminished oxidative damage in brain cells cultured in low levels of oxygen; they also diminished stem cell hyperplasia in the intestines of fruit flies. Brand says the study offers researchers a way to test the hypothesis that oxidative damage is specifically linked to disease. “For the first time we can test the effects of free radical damage in Alzheimer’s, Parkinson’s, cancer, type 2 diabetes, macular degeneration – you name it,” he said. “It gives you a target, and a drug candidate to hit that target.”
Given that the diseases Brand mentions are all associated with aging, he says the tool now gives researchers an opportunity to test the free radical theory of aging, which has dropped in popularity in the field, in large part because of the failure of antioxidant therapies. “We can start to answer questions that scientists have puzzled about for 50 years in terms of the specifics of oxidative damage,” he said. “We now have a precise tool to find out if the theory is correct. We can go into a biological system, see specifically what free radicals do and take preliminary steps to stop it.”
Citation: Suppressors of Superoxide/H2O2 Production at Site IQ of Mitochondrial Complex I Protect Against Stem Cell Hyperplasia and Ischemia/Reperfusion Injury
Other Buck researchers involved in the study include Renata L. S. Goncalves, Adam L. Orr, Akos A. Gerencser, Martin Borch Jensen, Simon Melov, Irina V. Perevoshchikova and Heinrich Jasper. Other collaborators include Leonardo Vargas, Carolina N. Turk, Jason T. Matzen, Victoria J. Dardov, H. Michael Petrassi, Shelly L. Meeusen, and Edward K. Ainscow of the Genomics Institute of the Novartis Research Foundation, San Diego, CA; and Yves T. Wang and Paul S. Brookes, the Department of Anaesthesiology, University of Rochester Medical Center, Rochester, New York, NY.
Acknowledgements: The work was supported by National Institutes of Health grants R01 AG033542 (M.D.B.), TL1 AG032116 (A.L.O.), GM100196 (H.J.), R01 HL127891 (P.S.B.) and The Ellison Medical Foundation grant AG-SS-2288-09 (M.D.B.). I.V.P. and R.L.S.G. received support from The Glenn Foundation- Buck Institute fellowship program. R.L.S.G. was also supported by the Brazilian Government through the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) eConselho de Nacional de Desenvolvimento Científico e Tecnológico programa Ciências Sem Fronteiras (CNPq-CSF). M.B.J. was supported by the Alfred Benzon Foundation.
Competing Financial Interests: L.V., C.N.T., J.T.M., V.J.D., H.M.P., S.L.M. and E.K.A. were employed by the Genomics Institute of the Novartis Research Foundation during the period of their contribution to this research. M.D.B. has consulted for Seahorse Bioscience. A.A.G. has a financial interest in Image Analyst Software.
About the Buck Institute for Research on Aging
The Buck Institute is the U.S.’s first independent research organization devoted to Geroscience – focused on the connection between normal aging and chronic disease. Based in Novato, California, the Buck is dedicated to extending “healthspan,” the healthy years of human life, and does so by utilizing a unique interdisciplinary approach involving laboratories studying the mechanisms of aging and those focused on specific diseases. Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer’s and Parkinson’s, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke. In their collaborative research, they are supported by the most recent developments in genomics, proteomics, bioinformatics and stem cell technologies. For more information: www.thebuck.org